Lonza Issues CORE RONOA Guidance to 16% for 2016
- Capital Markets Day focuses on how Lonza is shaping its profile
- All other guidance remains unchanged
Basel, Switzerland, 20 May 2014 – Lonza is welcoming analysts and investors to the company’s investor event at its Visp (CH) site from 20 to 21 May and offering them a close-up look at the company’s strategic drivers of change. As part of the additional financial information and insights provided into the business, Lonza is announcing that the expected CORE RONOA for 2016 is 16%. All other guidance remains unchanged. For more details on financial information to be provided during the Capital Markets Day, please click here.
The approximately 50 participants in Capital Markets Day 2014 will have the opportunity to learn more about individual businesses and segments, to hear updates on transformational initiatives and to visit the state-of-the-art manufacturing site in Visp for Antibody Drug Conjugates (ADCs).
All other Capital Markets Day presentations are also posted on the Investor Relations site of www.lonza.com.